- Home
- VBF vs CHRS Comparison
VBF vs CHRS Comparison
Compare VBF & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VBF
- CHRS
- Stock Information
- Founded
- VBF 1970
- CHRS 2010
- Country
- VBF United States
- CHRS United States
- Employees
- VBF N/A
- CHRS N/A
- Industry
- VBF Trusts Except Educational Religious and Charitable
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VBF Finance
- CHRS Health Care
- Exchange
- VBF Nasdaq
- CHRS Nasdaq
- Market Cap
- VBF 176.7M
- CHRS 84.2M
- IPO Year
- VBF N/A
- CHRS 2014
- Fundamental
- Price
- VBF $15.52
- CHRS $0.73
- Analyst Decision
- VBF
- CHRS Buy
- Analyst Count
- VBF 0
- CHRS 3
- Target Price
- VBF N/A
- CHRS $4.68
- AVG Volume (30 Days)
- VBF 45.5K
- CHRS 1.3M
- Earning Date
- VBF 01-01-0001
- CHRS 08-07-2025
- Dividend Yield
- VBF 5.18%
- CHRS N/A
- EPS Growth
- VBF N/A
- CHRS N/A
- EPS
- VBF N/A
- CHRS N/A
- Revenue
- VBF N/A
- CHRS $272,251,000.00
- Revenue This Year
- VBF N/A
- CHRS N/A
- Revenue Next Year
- VBF N/A
- CHRS $106.56
- P/E Ratio
- VBF N/A
- CHRS N/A
- Revenue Growth
- VBF N/A
- CHRS 19.87
- 52 Week Low
- VBF $13.68
- CHRS $0.66
- 52 Week High
- VBF $16.27
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- VBF 51.77
- CHRS 41.45
- Support Level
- VBF $15.41
- CHRS $0.72
- Resistance Level
- VBF $15.54
- CHRS $0.77
- Average True Range (ATR)
- VBF 0.10
- CHRS 0.04
- MACD
- VBF -0.01
- CHRS 0.00
- Stochastic Oscillator
- VBF 36.76
- CHRS 13.65
About VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.